OncoMatch/Clinical Trials/NCT06464861
Sequential Treatment of CD19 CARNK and 7x19 CAR-T in R/R B Cell Lymphoma
Is NCT06464861 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies CD19-CAR-NK/T for primary mediastinal b-cell lymphoma (pmbcl).
Treatment: CD19-CAR-NK/T — To study the safety and efficacy of cord blood-derived CD19 CAR-NK cells sequential with 7x19 CAR-T in relapse / refractory B cell lymphoma
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Diffuse Large B-Cell Lymphoma
Biomarker criteria
Required: CD19 expression (positive)
The puncture section of the tumor tissue was positive for CD19 expression
Required: CD20 wild-type
Previous treatment must include CD20 monoclonal antibody treatment (unless the subject is CD20 negative)
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: cd20 monoclonal antibody
Must have received: anthracycline
Cannot have received: gene therapy
Lab requirements
Kidney function
Creatinine clearance rate (Cockcroft-Gault method) ≥60 mL/min; Glomerular filtration rate >50 mL/min
Liver function
Alanine aminotransferase, aspartate aminotransferase ≤ 2.5× UNL; Serum total bilirubin and alkaline phosphatase ≤1.5× UNL
Cardiac function
Cardiac ejection fraction (EF) ≥50%; Subjects with Grade III or IV cardiac dysfunction according to the New York Heart Association's cardiac function grading criteria [excluded]
Sufficient organ function reserve: Alanine aminotransferase, aspartate aminotransferase ≤ 2.5× UNL; Creatinine clearance rate (Cockcroft-Gault method) ≥60 mL/min; Serum total bilirubin and alkaline phosphatase ≤1.5× UNL; Glomerular filtration rate >50 mL/min; Cardiac ejection fraction (EF) ≥50%; Under natural indoor air environment, basic oxygen saturation >92%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify